MinuteClinic CEO
This article was originally published in The Tan Sheet
Executive Summary
Former Arby's CEO James Howe will take over leadership of the Minneapolis-based operator of walk-in health clinics in preparation for "rapid expansion," MinuteClinic announces June 8. The exec was selected for his "extensive leadership experience, including growing and managing multi-location retail operations," the company states. Howe led Arby's from 1999 to 2004, and held previous positions at KFC, Helene Curtis and Procter & Gamble. Outgoing CEO Linda Hall Whitman will stay on as chief operating officer. The firm now operates in Cub Foods, Target and corporate and college campuses, and announced a deal with CVS last month (1"The Tan Sheet" May 9, 2005, In Brief)...
You may also be interested in...
CVS launches MinuteClinics
Pharmacy chain will open its first MinuteClinic at locations in Minneapolis, Minn. and Annapolis, Md. in June, CVS says April 28. The health centers offer basic diagnostic and screening services and are staffed by nurse practitioners or physician assistants. CVS CEO Tom Ryan called the partnership with the Minneapolis-based clinic chain "a natural extension of our overall mission," citing MinuteClinic's "proven ability to work collaboratively with physicians in the prompt diagnosis, treatment or referral of patients." MinuteClinic CEO Linda Whitman expressed the firm's intention to roll out nationally at the CHPA annual meeting in March (1"The Tan Sheet" March 21, 2005, p. 11)...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.